Testing genetic markers for early detection of myeloid cancers and bone marrow failure

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial utilizes next generation sequencing (NGS) to identify genetic markers associated with pre-myeloid cancers and bone marrow failure syndromes. The study aims to diagnose and prognosticate patients who exhibit precursor features of myeloid neoplasms but do not yet meet diagnostic criteria. Participants will undergo various biospecimen collections, including blood samples and biopsies, to facilitate genomic analysis. The findings may lead to earlier interventions and a better understanding of disease progression and risk factors.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with idiopathic cytopenias of unclear significance (ICUS)
* Patients with clonal hematopoiesis of indeterminate significance (clonal hematopoiesis of indeterminate potential \[CHIP\]), including the recently described CHIP syndrome called VEXAS (vacuoles, E1 ubiquitin ligase, X chromosomal, autoimmune and somatic)
* Patients with clonal cytopenias of undetermined significance (CCUS)
* Marrow failure syndromes with myeloid malignancy predisposition - telomere dysfunction, chromosomal breakage disorders
* Germ line inherited syndromes with risk for malignant transformation - GATA2, CEBPA, ETV-6, RUNX1, JAK2, PF6, etc.
* Low risk MDS (idiopathic dysplasia of unclear significance)
* Family member of a patient with one of the above conditions
* Patient at high risk or suspected of developing one of the above conditions

Exclusion Criteria:

* Patients under 18 years of age

Where it's running

• Mayo Clinic in Arizona
  Scottsdale, Arizona, United States Recruiting
• Mayo Clinic in Florida
  Jacksonville, Florida, United States Recruiting
• Mayo Clinic in Rochester
  Rochester, Minnesota, United States Recruiting

Study contacts

• Principal investigator: Mrinal S. Patnaik, MBBS — Mayo Clinic
• Study coordinator: Dani Rud
• Email: cimpmlresearch@mayo.edu
• Phone: 507-284-0228

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Early treatment for high-risk Clonal Cytopenia of Undetermined Significance

  This study is testing if an early treatment with a new oral medication can help people with high-risk Clonal Cytopenia of Undetermined Significance feel better and stay healthier over three years.

  Recruiting Early Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT06802146

• Investigating blood cancer risks in patients with ovarian and other solid tumors

  This study is trying to see if certain cancer treatments for ovarian and other solid tumors can increase the risk of blood cancers in patients.

  Recruiting University of Washington · Seattle, Washington · NCT06295965

• Understanding the natural progression of blood cell disorders

  This study is trying to understand how certain blood cell disorders develop over time in adults by looking at their genes and seeing if they are linked to blood cancers and other health issues.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT04102423

• Understanding congenital bone marrow failure and related disorders through a national network

  This project tests whether people with rare inherited bone marrow failure syndromes or related conditions really have the underlying genetic causes, by collecting data and samples across multiple centers.

  Recruiting at 4 sites Istituto Giannina Gaslini · Avellino and 3 other locations · NCT07877727

• See if virtual informed consent methods help people decide to join cancer research

  This trial tests whether virtual human communicators and different consent messages can influence cancer patients’ understanding and willingness to participate in research.

  Recruiting Mayo Clinic · Jacksonville, Florida · NCT07805083

• AI-powered supportive care chatbot for young adult cancer survivors

  A chatbot driven by artificial intelligence is tested to help young adult cancer survivors manage symptoms and care needs after treatment.

  Recruiting University of Michigan Rogel Cancer Center · Ann Arbor, Michigan · NCT07772596

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.